Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01789736 · ClinicalTrials.gov registry record · Phase 2
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Phase 2 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 234
- Enrollment target
NCT01789736: Completed Phase 2 study, sponsored by Aerie Pharmaceuticals.
NCT01789736 is a Phase 2 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 234 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01789736, a Phase 2 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 234 participants
- Enrollment target
Study Summary
In the double-masked, randomized, multi-center, active-controlled parallel study, patients will be randomized to receive either a fixed dose combination of AR-12286 and travoprost, AR-12286, or travoprost. The hypothesis is that there is no difference between each treatment arm.
Primary Outcome
The primary efficacy endpoint will be the mean diurnal IOP across subjects within treatment group and time point at Day 28.
Interventions
- DRUG PG286 Ophthalmic Solution 0.5%
- DRUG AR-12286 Ophthalmic Solution 0.5%
- DRUG Travoprost Ophthalmic Solution 0.004%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
What the finished NCT01789736 record still lists
NCT01789736 is an interventional study that assigns participants to a tested intervention. The registered 234 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% higher).
The record links to 0 conditions, and to 3 interventions - of which PG286 Ophthalmic Solution 0.5% is the first listed.
NCT01789736 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01789736 about?
NCT01789736 is a clinical study titled "A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days". In the double-masked, randomized, multi-center, active-controlled parallel study, patients will be randomized to receive either a fixed dose combination of AR-12286 and travoprost, AR-12286, or travoprost. The hypothesis is that there is no difference between each treatment arm.
What is the current status of trial NCT01789736?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2013-02. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01789736?
The interventions under investigation include: PG286 Ophthalmic Solution 0.5% (DRUG), AR-12286 Ophthalmic Solution 0.5% (DRUG), Travoprost Ophthalmic Solution 0.004% (DRUG).
Who is sponsoring clinical trial NCT01789736?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01789736's enrollment target sits among peer trials
234 255th of 2000 higher than 1,745 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
- NCT05444465 · 234 participants · NA
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
- NCT05720338 · 234 participants · Phase 3
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia